REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection

Patients with lymphoproliferative diseases are at high risk for SARS‐CoV‐2‐related complications and mortality. The role of casirivimab and imdevimab (REGEN‐COV), a neutralizing antibody cocktail, to treat immunocompromised hemato‐oncological patients with SARS‐CoV‐2 disease 2019 (Covid‐19) remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Bronstein, Yotam, Avivi, Irit, Cohen, Yael C, Feigin, Eugene, Perry, Chava, Herishanu, Yair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110987/
https://www.ncbi.nlm.nih.gov/pubmed/35602247
http://dx.doi.org/10.1002/jha2.403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110987/
https://www.ncbi.nlm.nih.gov/pubmed/35602247
http://dx.doi.org/10.1002/jha2.403

Ejemplares similares